NEWS:
Wednesday March 19 8:03 AM EDT
The Immune Response Corporation Receives United States Patent on Autoimmune Disease Technology
CARLSBAD, Calif., March 19 /PRNewswire/ -- The Immune Response Corp, announced today that it has received a patent from the United States Patent and Trademark Office, entitled Vaccination Against Diseases Resulting from Pathogenic Responses by Specific T Cell Populations.
The granted patent, Number 5612035, relates to technology developed by the company for the prevention or treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis. The Immune Response Corporation has already been granted patents from the European Patent Office and the Australian Industrial Property Organisation covering this technology. Recently, the company completed a Phase II clinical trial using this patented technology for rheumatoid arthritis. The treatment demonstrated safety and a statistically significant clinical improvement in disease condition using the American College of Rheumatology guidelines (ACR 20 criteria).
While the immune system is closely regulated, aberrations in immune response are not uncommon. In some instances, an individual's immune system functions inappropriately and attacks a component of the individual's body as if the component were foreign. The company believes certain T cells, known as autoreactive T cells, initiate this attack resulting in inflammation and destruction of normal tissue and the development of autoimmune diseases. The targets of this attack include synovium of the joints in rheumatoid arthritis, the skin in psoriasis and the myelin sheath in the brain and spinal cord in multiple sclerosis. The company has developed proprietary technology designed to reduce the severity or stop the attack of autoreactive T cells. This proprietary technology is covered by the issued patent.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, with technologies in four core areas: HIV, autoimmune disease, gene therapy and cancer. The company is conducting clinical trials using immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer and brain cancer, and preclinical studies for prostate cancer. The company is also developing gene therapy treatments for cardiovascular disease, hemophilia and hepatitis using a proprietary gene delivery system.
NOTE: The Immune Response Corporation news releases are available at no charge through PR Newswire's Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1995. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. SOURCE Immune Response Corporation |
